LONDON/COPENHAGEN (Reuters) – Novo Nordisk’s CEO Lars Fruergaard Jorgensen confirmed on Wednesday that Catalent’s Indiana plant in the United States has started filling injection pens for its obesity drug Wegovy, helping to boost output of the popular weekly injection.
The Indiana site is the third external production site doing so-called “fill-finish” for Novo’s Wegovy.
Novo has hired contract manufacturers and has some in-house capacity for filling syringes and packaging its pens.
(Reporting by Maggie Fick in London and Jacob Gronholt-Pedersen in Copenhagen; Writing by Josephine Mason in London, Editing by Louise Heavens)
Comments